gptkbp:instanceOf
|
gptkb:drug
|
gptkbp:approvalYear
|
2013
|
gptkbp:ATCCode
|
gptkb:J05AP08
|
gptkbp:bioavailability
|
high
|
gptkbp:brand
|
gptkb:Vemlidy
gptkb:Sovaldi
|
gptkbp:CASNumber
|
1190307-88-0
|
gptkbp:category
|
gptkb:NS5B_polymerase_inhibitor
nucleotide
direct-acting antiviral
|
gptkbp:contraindication
|
hypersensitivity to sofosbuvir
|
gptkbp:drugClass
|
antiviral drug
|
gptkbp:drugInteraction
|
gptkb:phenytoin
gptkb:rifampin
gptkb:ritonavir
gptkb:carbamazepine
gptkb:tipranavir
gptkb:St._John's_Wort
gptkb:oxcarbazepine
phenobarbital
amiodarone
|
gptkbp:eliminatedIn
|
renal
|
gptkbp:eliminationHalfLife
|
0.4 hours (sofosbuvir), 27 hours (GS-331007)
|
gptkbp:hasActiveMetabolite
|
gptkb:GS-331007
|
gptkbp:hasInChIKey
|
YYOQXSRSLFDJOM-QZIXMDIESA-N
|
gptkbp:hasMolecularFormula
|
C22H29FN3O9P
|
gptkbp:hasPatentExpiry
|
2029 (US)
|
gptkbp:hasPatentHolder
|
gptkb:Gilead_Sciences
|
gptkbp:hasSMILES
|
CC(C)COC(=O)[C@H](NC(=O)[C@@H]1O[C@@](C#N)(CO)[C@H](O)[C@@H]1O)P(=O)(OCC2=CC=CC=C2)OCC3=CC=CC=C3
|
gptkbp:hasUNII
|
SOF2X721MH
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB09052
|
gptkbp:indication
|
treatment of chronic hepatitis C infection
|
gptkbp:isProdrug
|
true
|
gptkbp:IUPACName
|
Isopropyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
|
gptkbp:legalStatus
|
prescription only
|
gptkbp:mechanismOfAction
|
NS5B RNA-dependent RNA polymerase inhibitor
|
gptkbp:metabolism
|
liver
|
gptkbp:molecularWeight
|
529.45
|
gptkbp:name
|
gptkb:Sofosbuvir
|
gptkbp:pregnancyCategory
|
B1 (Australia)
|
gptkbp:proteinBinding
|
61-65%
|
gptkbp:PubChem_CID
|
gptkb:DB09052
gptkb:D10366
45375808
CHEMBL1257078
28530408
|
gptkbp:routeOfAdministration
|
oral
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
headache
insomnia
|
gptkbp:status
|
true
|
gptkbp:synonym
|
gptkb:Sovaldi
gptkb:GS-7977
gptkb:PSI-7977
|
gptkbp:target
|
NS5B protein
|
gptkbp:bfsParent
|
gptkb:Tianeptine
|
gptkbp:bfsLayer
|
7
|